# A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke

> **NCT02072226** · PHASE3 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 313 (actual)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** Alteplase
- **DRUG:** Alteplase Placebo
- **DRUG:** Aspirin
- **DRUG:** Aspirin Placebo

## Key facts

- **NCT ID:** NCT02072226
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05-31
- **Primary completion:** 2017-03-22
- **Final completion:** 2017-03-22
- **Target enrollment:** 313 (ACTUAL)
- **Why stopped:** The study was terminated due to slow enrollment.
- **Last updated:** 2018-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02072226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02072226, "A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02072226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*